• 1
    Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22: 44157.
  • 2
    Marnini P, Colombo F, Cattaneo R, Geroli L, Venco A. Efficacy and tolerability of medium-term treatment with simvastatin in primary hypercholesterolaemia. Int J Clin Pharmacol Res 1992; 12: 6570.
  • 3
    Simons LA, Nestel PJ, Clifton P, Janus ED, Simons J, Parfitt A. Treatment of primary hypercholesterolaemia with pravastatin: efficacy and safety over three years. Med J Aust 1992; 157: 5849.
  • 4
    Gholami K, Tavakoli N, Maleki M, Shafiee A. Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia. J Clin Pharm Ther 1998; 23: 21321.
  • 5
    Iliadis EA, Rosenson RS. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 1999; 22: 258.
  • 6
    Horsmans Y, Desager JP, Harvengt C. Effects of combined bezafibrate-simvastatin appraised in healthy subjects. J Clin Pharmacol 1992; 32: 4226.
  • 7
    The European Malignant Hyperpyrexia Group (EMHG). A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56: 12679.
  • 8
    Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 1997; 145: 918.
  • 9
    Guis S, Jouglard J, Kozak-Ribbens G, Figarella-Branger D, Vanuxem D, Pellissier JF, et al. Malignant hyperthermia susceptibility revealed by myalgia and rhabdomyolysis during fluoroquinolone treatment. J Rheumatol 2001; 28: 14056.
  • 10
    Bendahan D, Kozak-Ribbens G, Confort-Gouny S, Ghattas B, Figarella-Branger D, Aubert M, et al. A noninvasive investigation of muscle energetics supports similarities between exertional heat stroke and malignant hyperthermia. Anesth Analg 2001; 93: 6839.
  • 11
    Kochling A, Wappler F, Winkler G, Schulte am Esch JS. Rhabdomyolysis following severe physical exercise in a patient with predisposition to malignant hyperthermia. Anaesth Intensive Care 1998; 26: 3158.
  • 12
    Wappler F, Fiege M, Steinfath M, Agarwal K, Scholz J, Singh S, et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 2001; 94: 95100.
  • 13
    Leeb T, Brenig B. Ryanodine receptors and their role in genetic diseases. Int J Mol Med 1998; 2: 293300.